ChiroptoLab opens in Peru to study bat-borne viruses
Published: 27 October 2026
The new state of the art lab is an animal facility focussed on understanding interactions between bats and viruses.

Over ten years of planning, construction and lab design led to the moment in September 2026 when the first bats were introduced to the Chiroptolab.
The capture team that brought them in (pictured above) includes the MRC-University of Glasgow Centre for Virus Research’s Daniel Streicker. The CVR operates the new Chiroptolab in collaboration with the Faculty of Veterinary Medicine of the National University of San Marcos (UNMSM) and the Center for Technological, Biomedical and Environmental Research (CITBM), both in Lima, Peru.
Bats (the Order Chiroptera) are the likely hosts of emerging and re-emerging viral zoonoses – diseases caused by viruses that pass from animals to humans.
These viruses could include Nipah virus, Hendra virus, Ebola virus, Marburg virus, Sosuga virus, SARS-Coronaviruses and rabies virus. Large-scale human alteration of landscapes may disturb the balance of contact between bats and their viruses, increasing virus “shedding” – the release of the viruses produced within infected bat cells. This could trigger “spillover” into human and animal populations. At the same time, there are not yet effective tools to prevent this transmission of viruses among bats or into human and/or domestic animal populations.

Our current understanding of the biology of bat-virus interactions comes largely from observational field studies and laboratory experiments on cells. Studies in live bats are crucial to turn discovery research into biomedical treatments or evidence-based activities that would prevent spillover. But there’s a problem - captive bat colonies suitable for virology research are still rare, globally.
The ChiroptoLab streamlines the integration of observational field studies in Peru with controlled experiments within a secure environment. The self-contained 161m2 facility contains ten separated areas, including a laboratory and three animal rooms for quarantine, experiments and a breeding colony.
The ChiroptoLab is the culmination of more than a decade of dedicated work by researchers in Peru and Scotland. Despite a pandemic, relocations, redesigns and false starts, we now have a Latin American resource that will enable excellent science and equitable international collaboration. From unravelling bat immunity to designing vaccines that block zoonotic transmission, the lab will advance One Health research and the prevention of zoonotic disease.”
Daniel Streiker, researcher at the MRC-University of Glasgow Centre for Virus Research
The One Health approach connects human health with the health of animals and our shared environment. The Chiropto Lab uses the common vampire bat, Desmodus rotundus, as an experimental model to study viral infections in bats.
Vampire bats are a pest species that is subjected to population control across Latin America due to the harm caused by bites associated with blood feeding. Vampire bats also spread rabies, a virus that kills tens of thousands of livestock annually. The virus is the primary source of lethal human rabies infections in the region, that occur when bats bite humans for blood meals.

The facility is a unique resource for Peru and Latin America. It allows in vivo experiments to fill the knowledge gap around the host response to viral infections, the bat immune system and viral response to stressors. These studies will contribute to the understanding of how viruses spillover from bats, and ultimately could have implications for predicting, preventing, and controlling it.
As well as studying transmission, ChiroptoLab researchers are also working to understand the immune response to rabies infection, which is vital for predicting the spread of diseases across populations. Understanding why some bats naturally resist rabies could inform the development of future medical interventions.
Finally, the lab team are scoping new vaccine platforms that would spread themselves among bats, producing immunity against harmful viruses. This novel approach to protect human health by containing viruses in bats before they spill over into humans may reduce the health and economic burden of rabies, and potentially other zoonoses as well. The team are particularly interested in studying a bat-specific betaherpesvirus - a promising platform to create a recombinant, self-spreading rabies vaccine.
Pictured at top, left to right: Carlos Tello, Lina Violet Lozano, Illariy Quintero, Daniel Streicker, Nardus Mollentze. Photo credit: Danel Montes
First published: 27 October 2026
<< News